Roche nabs pri­or­i­ty re­view for Eylea com­peti­tor; Italy's An­geli­ni eyes CNS, rare dis­ease star­tups with $35M Lu­mi­ra fund

The teams at Roche and Genen­tech are off and run­ning at the FDA, with reg­u­la­tors ac­cept­ing a quick pitch for what would be the first bis­pe­cif­ic an­ti­body de­signed for the eye.

Roche an­nounced late Wednes­day that its ap­pli­ca­tion for faricimab has been ac­cept­ed un­der pri­or­i­ty re­view to treat wet AMD and di­a­bet­ic mac­u­lar ede­ma. In ad­di­tion, the sub­mis­sion for di­a­bet­ic retinopa­thy was al­so ac­cept­ed, the com­pa­ny said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER